X4 Pharmaceuticals, Inc financial data

Symbol
XFOR on Nasdaq, XFORW, XFOWW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
61 North Beacon Street, 4 Th Floor, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Arsanis, Inc. (to 3/13/2019)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 537 % +36%
Debt-to-equity 224 % +89.6%
Return On Equity -275 % -56.2%
Return On Assets -85.1 % -5.19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 168 M shares +37.4%
Common Stock, Shares, Outstanding 168 M shares +37.4%
Entity Public Float 318 M USD +974%
Common Stock, Value, Issued 168 K USD +37.7%
Weighted Average Number of Shares Outstanding, Basic 200 M shares +37%
Weighted Average Number of Shares Outstanding, Diluted 200 M shares +37%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 69.8 M USD +1.16%
General and Administrative Expense 45.7 M USD +71.8%
Operating Income (Loss) -116 M USD -20.8%
Nonoperating Income (Expense) -13.3 M USD -4222%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -129 M USD -34.3%
Income Tax Expense (Benefit) 93 K USD +933%
Net Income (Loss) Attributable to Parent -129 M USD -34.4%
Earnings Per Share, Basic -0.67 USD/shares +30.2%
Earnings Per Share, Diluted -0.67 USD/shares +30.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.5 M USD -35.2%
Cash, Cash Equivalents, and Short-term Investments 80.9 M USD
Assets, Current 87.3 M USD -11.1%
Property, Plant and Equipment, Net 742 K USD -24.7%
Operating Lease, Right-of-Use Asset 5.26 M USD -23.1%
Goodwill 17.4 M USD 0%
Other Assets, Noncurrent 1.49 M USD +48.9%
Assets 112 M USD -9.83%
Accounts Payable, Current 8.94 M USD +49.1%
Employee-related Liabilities, Current 7.42 M USD +170%
Accrued Liabilities, Current 13.5 M USD +14.5%
Liabilities, Current 23.5 M USD +20.8%
Operating Lease, Liability, Noncurrent 2.32 M USD -31.4%
Other Liabilities, Noncurrent 1.03 M USD +193%
Liabilities 111 M USD +52.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -155 K USD -30.3%
Retained Earnings (Accumulated Deficit) -530 M USD -32.2%
Stockholders' Equity Attributable to Parent 1.04 M USD -98%
Liabilities and Equity 112 M USD -9.83%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -104 M USD -26.7%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities -5.32 M USD -59033%
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 168 M shares +37.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -39 M USD -36.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.3 M USD -35.1%
Deferred Tax Assets, Valuation Allowance 164 M USD +23.2%
Deferred Tax Assets, Gross 165 M USD +22.7%
Operating Lease, Liability 3.45 M USD -24.2%
Lessee, Operating Lease, Liability, to be Paid 4.1 M USD -27.6%
Property, Plant and Equipment, Gross 2.41 M USD +2.99%
Operating Lease, Liability, Current 1.13 M USD -3.57%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.33 M USD -5.12%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4 M USD +1.89%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 649 K USD -41.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 282 K USD -78.9%
Deferred Tax Assets, Operating Loss Carryforwards 123 M USD +14.6%
Unrecognized Tax Benefits 200 K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 47 K USD -83.5%
Operating Lease, Payments 1.38 M USD +1.84%
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 62 K USD -51.2%
Deferred Tax Assets, Net of Valuation Allowance 1.14 M USD -24.3%
Share-based Payment Arrangement, Expense 8.78 M USD +63.1%
Interest Expense 6.54 M USD +56.2%